Payment overview · 2025
General Payments
$201.74
8 reported records · 4 companies
Healthcare provider profile · identity verified
Mark Ward, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · SPARTANBURG, SC · NPI 1194791061
Verified facts
What the public records show
CMS Open Payments records show Mark Ward, M.D. received $201.74 in general payments during 2025 across 8 reported records.
PFIZER INC. accounted for 43.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 177 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $87.02 | 43.1% | 5 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $79.65 | 39.5% | 1 | 2025 |
| Inari Medical, Inc. | Unresolved — no canonical attribution shown | $20.78 | 10.3% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $14.29 | 7.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $201.74 | 8 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $79.65 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $68.62 | 4 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $68.62 | 4 | 2025 |
Source payment records
|
|||||
| CT THROMBECTOMY SYSTEM KIT Normalized: ct thrombectomy system kit |
Device | Inari Medical, Inc. | $20.78 | 1 | 2025 |
Source payment records
|
|||||
| FLOWTRIEVER CATHETER, S Normalized: flowtriever catheter s |
Device | Inari Medical, Inc. | $20.78 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $14.29 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $14.29 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
177 | 50 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
33 | 32 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 845 | 230 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 707 | 203 |
| Amlodipine Besylate | Amlodipine Besylate | 668 | 183 |
| Losartan Potassium | Losartan Potassium | 605 | 167 |
| Levothyroxine Sodium | Levothyroxine Sodium | 466 | 116 |
| Montelukast Sodium | Montelukast Sodium | 376 | 105 |
| Lisinopril | Lisinopril | 334 | 94 |
| Omeprazole | Omeprazole | 333 | 93 |
| Metformin Hcl | Metformin Hcl | 321 | 89 |
| Metoprolol Succinate | Metoprolol Succinate | 311 | 82 |
| Fluticasone Propionate | Fluticasone Propionate | 299 | 86 |
| Pantoprazole Sodium | Pantoprazole Sodium | 292 | 83 |
| Potassium Chloride | Potassium Chloride | 275 | 87 |
| Simvastatin | Simvastatin | 270 | 74 |
| Sertraline Hcl | Sertraline Hcl | 258 | 63 |
| Hydrochlorothiazide | Hydrochlorothiazide | 228 | 60 |
| Allopurinol | Allopurinol | 206 | 57 |
| Gabapentin | Gabapentin | 206 | 57 |
| Metoprolol Tartrate | Metoprolol Tartrate | 206 | 54 |
| Trazodone Hcl | Trazodone Hcl | 198 | 55 |
| Tamsulosin Hcl | Tamsulosin Hcl | 188 | 56 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 182 | 48 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 180 | 60 |
| Eliquis | Apixaban | 177 | 50 |
| Lorazepam | Lorazepam | 168 | 34 |
| Pravastatin Sodium | Pravastatin Sodium | 154 | 39 |
| Tramadol Hcl | Tramadol Hcl | 150 | 27 |
| Ezetimibe | Ezetimibe | 142 | 51 |
| Furosemide | Furosemide | 132 | 51 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 130 | 38 |
| Jardiance | Empagliflozin | 126 | 30 |
| Duloxetine Hcl | Duloxetine Hcl | 123 | 34 |
| Carvedilol | Carvedilol | 122 | 40 |
| Ozempic | Semaglutide | 118 | 23 |
| Synthroid | Levothyroxine Sodium | 116 | 34 |
| Zolpidem Tartrate | Zolpidem Tartrate | 116 | 24 |
| Alprazolam | Alprazolam | 115 | 16 |
| Meloxicam | Meloxicam | 110 | 29 |
| Alendronate Sodium | Alendronate Sodium | 106 | 32 |
| Ibandronate Sodium | Ibandronate Sodium | 103 | 30 |
| Spironolactone | Spironolactone | 103 | 30 |
| Escitalopram Oxalate | Escitalopram Oxalate | 99 | 35 |
| Pregabalin | Pregabalin | 94 | 30 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 94 | 20 |
| Clopidogrel | Clopidogrel Bisulfate | 92 | 26 |
| Famotidine | Famotidine | 91 | 28 |
| Celecoxib | Celecoxib | 86 | 28 |
| Buspirone Hcl | Buspirone Hcl | 82 | 21 |
| Farxiga | Dapagliflozin Propanediol | 80 | 18 |
| Mounjaro | Tirzepatide | 78 | 15 |
| Atenolol | Atenolol | 77 | 25 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 76 | 21 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 73 | 16 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 71 | 58 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 66 | 13 |
| Azithromycin | Azithromycin | 65 | 54 |
| Citalopram Hbr | Citalopram Hydrobromide | 60 | 17 |
| Valsartan | Valsartan | 60 | 16 |
| Rybelsus | Semaglutide | 55 | suppressed |
| Mirtazapine | Mirtazapine | 54 | 15 |
| Glipizide Er | Glipizide | 53 | 15 |
| Prednisone | Prednisone | 51 | 40 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 49 | 14 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 49 | 14 |
| Fluoxetine Hcl | Fluoxetine Hcl | 48 | 11 |
| Clonazepam | Clonazepam | 46 | suppressed |
| Glipizide | Glipizide | 46 | 14 |
| Warfarin Sodium | Warfarin Sodium | 45 | 14 |
| Chlorthalidone | Chlorthalidone | 43 | 12 |
| Lovastatin | Lovastatin | 43 | suppressed |
| Xarelto | Rivaroxaban | 43 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 41 | 15 |
| Tizanidine Hcl | Tizanidine Hcl | 40 | 17 |
| Doxazosin Mesylate | Doxazosin Mesylate | 38 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 38 | 22 |
| Finasteride | Finasteride | 36 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 36 | 13 |
| Paroxetine Hcl | Paroxetine Hcl | 36 | suppressed |
| Amoxicillin | Amoxicillin | 35 | 32 |
| Memantine Hcl | Memantine Hcl | 34 | 13 |
| Nebivolol Hcl | Nebivolol Hcl | 34 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 34 | suppressed |
| Telmisartan | Telmisartan | 34 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 33 | 32 |
| Valacyclovir | Valacyclovir Hcl | 33 | 14 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 31 | suppressed |
| Bupropion Xl | Bupropion Hcl | 30 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 30 | 12 |
| Entresto | Sacubitril/Valsartan | 30 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 30 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 30 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 30 | 24 |
| Benazepril Hcl | Benazepril Hcl | 29 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 28 | suppressed |
| Fenofibrate | Fenofibrate | 28 | suppressed |
| Topiramate | Topiramate | 28 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 26 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 26 | 14 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 26 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 25 | 24 |
| Symbicort | Budesonide/Formoterol Fumarate | 25 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 24 | suppressed |
| Lansoprazole | Lansoprazole | 24 | suppressed |
| Repatha Sureclick | Evolocumab | 24 | suppressed |
| Temazepam | Temazepam | 24 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 23 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 23 | suppressed |
| Myrbetriq | Mirabegron | 21 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 20 | suppressed |
| Glimepiride | Glimepiride | 20 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 19 | suppressed |
| Diazepam | Diazepam | 19 | suppressed |
| Minoxidil | Minoxidil | 19 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 19 | suppressed |
| Hydrocortisone | Hydrocortisone | 18 | suppressed |
| Nystatin | Nystatin | 18 | suppressed |
| Primidone | Primidone | 18 | suppressed |
| Ramipril | Ramipril | 18 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 17 | suppressed |
| Dutasteride | Dutasteride | 16 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 16 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 16 | suppressed |
| Nitroglycerin | Nitroglycerin | 16 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Bumetanide | Bumetanide | 15 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 15 | suppressed |
| Felodipine Er | Felodipine | 15 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 15 | suppressed |
| Belsomra | Suvorexant | 14 | suppressed |
| Methimazole | Methimazole | 14 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 13 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 13 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 13 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 13 | suppressed |
| Epinephrine | Epinephrine | 13 | suppressed |
| Indapamide | Indapamide | 13 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 13 | suppressed |
| Pentoxifylline | Pentoxifylline | 13 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 12 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 12 | 11 |
| Droplet Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Fluconazole | Fluconazole | 12 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 12 | 12 |
| Irbesartan | Irbesartan | 12 | suppressed |
| Klor-Con M20 | Potassium Chloride | 12 | suppressed |
| Levetiracetam | Levetiracetam | 12 | suppressed |
| Linzess | Linaclotide | 12 | suppressed |
| Ondansetron Odt | Ondansetron | 12 | suppressed |
| Acyclovir | Acyclovir | 11 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 11 | suppressed |
| Naproxen | Naproxen | 11 | suppressed |
| Nifedipine Er | Nifedipine | 11 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 11 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $201.74 · 8 records | PFIZER INC. | CT THROMBECTOMY SYSTEM KIT, FLOWTRIEVER CATHETER, S, NURTEC ODT, OTEZLA, REPATHA, The Cologuard Plus Collection Kit, ZAVZPRET | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with PFIZER INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error